Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A study evaluating the safety of a high and low dose of PPM-204 on the electrical pathways of the heart.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Criteria

Inclusion Criteria:

• Men or women, aged 18 to 55 years

• Body mass index in the range of 18 to 30 kg/m2

• Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG

Exclusion Criteria:

• History of cardiac, thyroid, muscle, or kidney abnormalities

• A family history of long QT syndrome and/or sudden cardiac death

• History of any clinically significant drug allergy, hypersensitivity to sulfonomides or the quinolone class of antibiotics